
Albert Bourla
The veterinarian-turned-CEO who led Pfizer’s COVID-19 vaccine effort and now steers the drugmaker through the post-pandemic slump.
Read Albert Bourla’s net worth & biography →
Pay vs performance
what happened while they earned itNo score, no opinion. Compensation is filed; stock and S&P are market returns over the window shown, closes through Oct 9, 2026; revenue and EPS are latest reported vs the prior year. You decide.
Why this pay?
- His fiscal 2025 Summary Compensation Table total was $27.6 million, roughly 92% performance-based — a mix of salary, cash incentive, and the grant value of stock and options — equal to about 277 times the company’s median employee pay.
Quick facts
Compensation breakdown
DEF 14A~92% performance-based; ~277x the median employee. Source: Pfizer 2026 Proxy (FY2025) →
Compensation history
salary + cash vs stock, from the proxiesRelated intelligence
every filing on Pfizer, one hop awayCareer
Compare pay with
Every figure ties to a filing. Compensation is the total from Pfizer's Summary Compensation Table for FY2025 (grant-date values, which can differ from what an executive realizes when awards vest). We publish what the filings say, and we don't grade people. Photo: World Economic Forum / CC BY 3.0 / Wikimedia Commons.